| Issue |
J Extra Corpor Technol
Volume 55, Number 3, September 2023
|
|
|---|---|---|
| Page(s) | 130 - 133 | |
| DOI | https://doi.org/10.1051/ject/2023025 | |
| Published online | 08 September 2023 | |
Case Report
Use of hepatic support with MARS in a patient with SARS-CoV-2 Pneumonia, in treatment with ECMO and CRRT therapies: Case Report
1
Internal Medicine Resident, Department of Health Sciences, Christus Muguerza Health System, UDEM, 64060 Monterrey, Nuevo Leon, Mexico
2
Pediatrics, Director of the ECMO Unit, Christus Muguerza Health System, UDEM, 64060 Monterrey, Nuevo Leon, Mexico
3
Critical Medicine, Internal Medicine, Internal Medicine Professor, Department of Health Sciences, Christus Muguerza Health System, UDEM, 64060 Monterrey, Nuevo Leon, Mexico
4
Nephrology of the Critically Ill Patient, Internal Medicine, Internal Medicine Professor, Department of Health Sciences, Christus Muguerza Health System, UDEM, 64060 Monterrey, Nuevo Leon, Mexico
5
Associate Professor of Nephrology Service, Hospital Universitario “José Eleuterio González”, UANL, 64460 Monterrey, Nuevo Leon, Mexico
* Corresponding author: drcesarrdzsalinas@gmail.com
Received:
12
August
2022
Accepted:
5
July
2023
Extracorporeal Membrane Oxygenation (ECMO) therapy had an important role in the treatment of severe COVID-19 pneumonia, where invasive mechanical ventilation was not enough to provide correct oxygenation to various organ systems. However, there are other extracorporeal technologies, such as the Molecular Absorbent Recirculation System (MARS) and Continuous Renal Replacement Therapy (CRRT), that provide temporal support for any critical patient. The following case describes a 60-year-old man with severe Acute Respiratory Distress Syndrome (ARDS), who needed ECMO therapy. During the critical days of hospitalization, CRRT was used, but a sudden hyperbilirubinemia ensued. Consequently, MARS therapy was initiated; followed by an improvement of bilirubin levels. Additional studies are needed to establish the possible benefits of the combination of MARS therapy and ECMO; however, we detected that concomitantly, there was a decrease in other laboratory parameters such as acute phase reactants. Even though, no change in clinical course was observed, as shown in some studies.
Key words: Extracorporeal membrane oxygenation / Continuous renal replacement therapy / COVID-19 / Acute respiratory distress syndrome / MARS
© The Author(s), published by EDP Sciences, 2023
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.